Bringing you live news and features since 2006 

Solactive and Evaluate launch Solactive Evaluate Global Pharma Index, their first co-branded index


Solactive and Evaluate launch the Solactive Evaulate Global Pharma Index, which aims to represent securities with potential future revenues in the pharmaceutical industry.

With rapid advancements in medical research, technology, and increasing global demand for healthcare, the pharmaceutical industry is expected to experience substantial growth in the coming years. The Covid-19 pandemic has highlighted the crucial role of pharmaceutical companies in developing vaccines and therapeutics, driving investments and innovation in the sector. Additionally, the aging population and the prevalence of chronic diseases continue to drive the demand for innovative drugs and treatments. According to Evaluate Pharma, only prescription drug sales are forecast to grow at an annualised rate of 5.9 per cent between 2023 and 2028, increasing from USD1.1 trillion to USD1.6 trillion. Envisaging this potential, Solactive aims to leverage its open architecture approach and partnered with Evaluate, a Norstella company, to launch the Solactive Evaluate Global Pharma Index. 

The Solactive Evaluate Global Pharma Index represents securities with potential future revenues in the pharmaceutical industry. To be eligible for inclusion in the index, a company’s total estimated future five-year revenues must exceed USD1 million and be derived from products and services in the following therapeutic areas: blood, cancer, cardiovascular, diabetes, gastrointestinal, hepatic & biliary, HIV & related conditions, hormone, immunology, infections, miscellaneous, musculoskeletal, neurology, psychiatry, oncology, reproduction, respiratory, sensory organs, skin, surgery, and urinary tract. 

Timo Pfeiffer, Chief Markets Officer at Solactive, comments: “We are thrilled to partner with Evaluate to launch our first co-branded index with them, in a sector that plays a crucial role in advancing healthcare and addressing global challenges of our society. This collaboration highlights Solactive‘s open architecture approach and Evaluate’s expertise in pharmaceutical insight, enabling us to leverage their knowledge and provide an index with a comprehensive representation of securities in the pharmaceutical industry. We look forward to continuing our partnership and developing more solutions together for the investment community.”

Evaluate’s Chief Data Operations Officer, Kevin Morgan, comments: “The importance of high-quality insight and forecasting in the pharmaceutical industry is critical for successful investments. By combining the capabilities and expertise of Evaluate and Solactive, this new index will enable the investment and trading community to benchmark key areas of growth, emerging pharmaceutical technologies, and clinical innovations that will enable them to make effective investment decisions.”

Latest News

The August data from LSEG Lipper shows that the global ETF industry held USD10,547.4 billion in assets under management on..
HANetf has announced that their European Green Deal UCITS ETF (ticker: EUGD) has reached USD52 million (EUR49.9 million) in assets..
Legal & General Investment Management (LGIM) has announced the launch of the L&G Global Brands UCITS ETF. The firm writes..
Vienna Stock Exchange has launched three new thematic indices: CECE Reshoring, CECE Commodity Producers and CECE Clean Energy, writing that..

Related Articles

John Ciampaglia, Sprott Asset Management
Geo-political tensions and concerns about hitting clean energy targets have brought the focus back onto nuclear power in recent months,...
Nick King, Robeco
Europeam investment management giant Robeco has announced the appointment of Nick King as Head of Exchange Traded Funds (ETFs), in...
Kristof Gleich, Harbor Capital
Harbor Capital burst onto the ETF issuance world in 2021 and now has USD1.1 billion in assets in ETFs. But...
Europe’s thematic ETF provider, Rize ETF, has been acquired by ARK Invest LLC, the parent of ARK Investment Management LLC,...
Subscribe to the ETF Express newsletter

Subscribe for access to our weekly newsletter, newsletter archive, updates on the site and exclusive email content.

Marketing by